Optimizing tumor-reactive γδ T cells for antibody-based cancer immunotherapy

Current Molecular Medicine

Volumn 10, Issue 8, 2010, Pages 719-726

  Meraviglia, S ^a   Caccamo, N ^a   Guggino, G ^a   Tolomeo, M ^a   Siragusa, S ^a   Stassi, G ^a   Dieli, F ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

ADCC; Cancer; Immunotherapy; Monoclonal antibodies; V 9V 2 T cells

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; CAMPATH 1HTM; CD16 ANTIGEN; CD20 ANTIBODY; CD33 ANTIGEN; CD59 ANTIGEN; CD64 ANTIGEN; CETUXIMAB; DECAY ACCELERATING FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIB; FLUOROURACIL; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; INFLIXIMAB; INTERLEUKIN 2; MONOCLONAL ANTIBODY; NATURAL KILLER CELL RECEPTOR NKG2D; OKT 3; PANITUMUMAB; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG ACTIVITY; EFFECTOR CELL; GAMMA DELTA T LYMPHOCYTE; GRAFT REJECTION; HEAD AND NECK TUMOR; HUMAN; LYMPHOMA; NATURAL KILLER CELL; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TARGET CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; NEOPLASMS; RECEPTOR, ERBB-2; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RECEPTORS, IGG; T-LYMPHOCYTES;

EID: 78651320948     PISSN: 15665240     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652410793384150     Document Type: Article

References (99)

1. Borghaei H, Smith MR, Campbell KS. Immunotherapy ofcancer. Eur J Pharmacol 2009; 625: 41-54.
2. van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, vanOers MH. Complement activation plays a key role in the sideeffectsof rituximab treatment. Br J Haematol 2001; 115: 807-11.
3. Weng WK, Levy R. Expression of complement inhibitorsCD46, CD55, and CD59 on tumor cells does not predictclinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 2001; 98: 1352-7.
4. Bellosillo B, Villamor N, Lopez-Guillermo A, et al. Complement-mediated cell death induced by rituximab in Bcelllymphoproliferative disorders is mediated in vitro by acaspase-independent mechanism involving the generation ofreactive oxygen species. Blood 2001; 98: 2771-7.
5. Idusogie EE, Wong PY, Presta LG, et al. Engineeredantibodies with increased activity to recruit complement. JImmunol 2001; 166: 2571-5.
6. Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20)therapy of B-cell lymphomas: direct complement killing issuperior to cellular effector mechanisms. Scand J Immunol 2000; 51: 634-41.
7. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of Blymphoma cells to anti-CD20 monoclonal antibody rituximabin vitro: CD55 and CD59 regulate complement-mediated celllysis. Blood 2000; 95: 3900-8.
8. Beum PV, Lindorfer MA, Taylor RP. Within peripheral bloodmononuclear cells, antibody-dependent cellular cytotoxicityof rituximab-opsonized Daudi cells is promoted by NK cellsand inhibited by monocytes due to shaving. J Immunol 2008; 181: 2916-24.
9. Kunq P, Goldstein G, Reinhen EL, Schlossman SF. Monoclonal antibodies defining distinctive human T cellsurface antigens. Science 1979; 206: 347-9.
10. Reff ME, Carner K, Chambers KS, et al. Depletion of B cellsin vivo by a chimeric mouse human monoclonal antibody toCD20. Blood 1994; 83: 435-45.
11. Pescovitz MD. Rituximab, an anti-CD20 monoclonalantibody: history and mechanism of action. Am J Transplant 2006; 6: 859-66.
12. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanismsof killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007; 44: 3823-37.
13. Carter P, Presta L, Gorman CM, et al. Humanization of anantip185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89: 4285-9.
14. Hudis CA. Trastuzumab-mechanism of action and use inclinical practice. N Engl J Med 2007; 357: 39-51.
15. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumourbiology: herceptin acts as an anti-angiogenic cocktail. Nature 2002; 416: 279-80.
16. Barok M, Balázs M, Nagy P, et al. Trastuzumab causesantibody-dependent cellular cytotoxicity mediated growthinhibition of submacroscopic JIMT-1 breast cancerxenografts despite intrinsic drug resistance. Mol Cancer Ther 2007; 6: 2065-72.
17. Hale G, Dyer MJ, Clark MR, et al. Remission induction innon-Hodgkin lymphoma with reshaped human monoclonalantibody CAMPATH-1H. Lancet 1988; 2: 1394-9.
18. Hale G, Hoang T, Prospero T, Watt SM, Waldmann H. Removal of T cells from bone marrow for transplantation: amonoclonal anti lymphocyte antibody that fixes humancomplement. Blood 1983; 62: 873-82.
19. Mendelsohn J. Epidermal growth factor receptor inhibition bya monoclonal antibody as anticancer therapy. Clin Cancer Res 1997; 3: 2703-7.
20. Galizia G, Lieto E, De Vita F, et al. Cetuximab, a chimerichuman mouse anti-epidermal growth factor receptormonoclonal antibody, in the treatment of human colorectalcancer. Oncogene 2007; 26: 3654-60.
21. Kawaguchi Y, Kono K, Mimura K, et al. Cetuximab induceantibody-dependent cellular cytotoxicity against EGFRexpressingesophageal squamous cell carcinoma. Int JCancer 2007; 120: 781-7.
22. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelialgrowth factor-induced angiogenesis suppresses tumourgrowth in vivo. Nature 1993; 362: 841-4.
23. Presta LG, Chen H, O'Connor SJ, et al. Humanization of anantivascular endothelial growth factor monoclonal antibodyfor the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593-9.
24. Kramer I, Lipp HP. Bevacizumab, a humanized antiangiogenicmonoclonal antibody for the treatment ofcolorectal cancer. J Clin Pharm Ther 2007; 32: 1-14.
25. Cohenuram M, Saif MW. Panitumumab the first fully humanmonoclonal antibody: from the bench to the clinic. Anticancer Drugs 2007; 18: 7-15.
26. Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G. From Xeno Mouse technology to panitumumab, the first fullyhuman antibody product from transgenic mice. Nat Biotechnol 2007; 25: 1134-43.
27. Hamann PR, Hinman LM, Hollander I, et al. Gemtuzumabozogamicin, a potent and selective anti-CD33 antibodycalicheamicinconjugate for treatment of acute myeloidleukemia. Bioconjug Chem 2002; 13: 47-58.
28. Pagano L, Fianchi L, Caira M, Rutella S, Leone G. The roleof gemtuzumab ozogamicin in the treatment of acute myeloidleukemia patients. Oncogene 2007; 26: 3679-90.
29. Chinn PC, Leonard JE, Rosenberg J, Hanna N, Anderson DR. Preclinical evaluation of 90Y-labeled anti-CD20monoclonal antibody for treatment of non-Hodgkin'slymphoma. Int J Oncol 1999; 15: 1017-25.
30. Davies AJ. Radioimmunotherapy for B-cell lymphoma: Y90ibritumomab tiuxetan and I(131) tositumomab. Oncogene 2007; 26: 3614-28.
31. Nadler LM, Ritz J, Hardy R, et al. A unique cell surfaceantigen identifying lymphoid malignancies of B cell origin. JClin Invest 1981; 67: 134-40.
32. Zalutsky MR, Garg PK, Narula AS. Labeling monoclonalantibodies with halogen nuclides. Acta Radiol 1990; 374: 141-5.
33. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study ofiodine I 131 tositumomab for chemotherapy refractory lowgrade or transformed low grade B-cell non-Hodgkin'slymphomas. J Clin Oncol 2001; 19: 3918-28.
34. Nimmerjahn F, Ravetch JV. Fcnnnreceptors as regulators ofimmune responses. Nat Rev Immunol 2008; 8: 34-47.
35. Ravetch JV, Bolland S. Ig G Fc receptors. Annu Rev Immunol 2001; 19: 275-90.
36. Barnes N, Gavin AL, Tan PS, et al. FcγRI-deficient miceshow multiple alterations to inflammatory and immuneresponses. Immunity 2002; 16: 379-89.
37. Ioan-Facsinay A, de Kimpe SJ, Hellwig SM, et al. FcγRI(CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterialinfection. Immunity 2002; 16: 391-402.
38. Bevaart L, Jansen MJ, van Vugt MJ, et al. The high affinityIg G receptor, FcγRI, plays a central role in antibody therapyof experimental melanoma. Cancer Res 2006; 66: 1261-4.
39. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fcreceptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443-6.
40. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity ofhumanized anti-CD20 monoclonal antibody andpolymorphism in Ig G Fc receptor FcγRIIIa gene. Blood 2002; 99: 754-8.
41. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotypevaccination is correlated with humoral immune response andimmunoglobulin G Fc receptor genotype. J Clin Oncol 2004; 22: 4717-24.
42. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin Gsubclass activity through selective Fc receptor binding. Science 2005; 310: 1510-2.
43. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody isotype-specific engagement of Fcγ receptorsregulates B lymphocyte depletion during CD20immunotherapy. J Exp Med 2006; 203: 743-53.
44. Iannello A, Ahmad A. Role of antibody dependent cellmediatedcytotoxicity in the efficacy of therapeutic anticancermonoclonal antibodies. Cancer Metastasis Rev 2005; 24: 487-99.
45. Perussia B. Fc receptors on natural killer. Curr Top Microbiol Immunol 1998; 230: 63-88.
46. Selvaraj P, Fifadara N, Nagarajan S, Cimino A, Wang G. Functional regulation of human neutrophil Fcγ receptors. Immunol Res 2004; 29: 219-30.
47. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fcreceptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443-6.
48. Weng WK, Levy R. Two immunoglobulin G fragment Creceptor polymorphisms independently predict response torituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940-7.
49. Gennari R, Menard S, Fagnoni F, et al. Pilot study of themechanism of action of preoperative trastuzumab in patientswith primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004; 10: 5650-5.
50. Taylor RJ, Chan SL, Wood A, et al. FcγRIIIa polymorphismsand cetuximab induced cytotoxicity in squamous cellcarcinoma of the head and neck. Cancer Immunol Immunother 2009; 58: 997-1006.
51. Louis E, El Ghoul Z, Vermeire S, et al. Association betweenpolymorphism in Ig G Fc receptor IIIa coding gene andbiological response to infliximab in Crohn's disease. Aliment Pharmacol Ther 2004; 19: 511-9.
52. Reff ME, Carner K, Chambers KS, et al. Depletion of B cellsin vivo by a chimeric mouse human monoclonal antibody toCD20. Blood 1994; 83: 435-45.
53. Cooley S, Burns LJ, Repka T, Miller JS. Natural killer cellcytotoxicity of breast cancer targets is enhanced by twodistinct mechanisms of antibody dependent cellularcytotoxicity against LFA-3 and HER2/neu. Exp Hematol 1999; 27: 1533-41.
54. Sliwkowski MX, Lofgren JA, Lewis GD, et al. Non clinicalstudies addressing the mechanism of action of trastuzumab(Herceptin). Semin Oncol 1999; 26: 60-70.
55. Golay J, Cortiana C, Manganini M. The sensitivity of acutelymphoblastic leukemia cells carrying the t (12; 21)translocation to campath-1H-mediated cell lysis. Haematologica 2006; 91: 322-30.
56. Golay J, Manganini M, Rambaldi A, Introna M. Effect ofalemtuzumab on neoplastic B cells. Haematologica 2004; 89: 1476-83.
57. Cartron G, Watier H, Golay J, Solal-Celigny P. From thebench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104: 2635-42.
58. Ljunggren HG, Malmberg KJ. Prospects for the use of NKcells in immunotherapy of human cancer. Nat Rev Immunol 2007; 7: 329-339.
59. Shields RL, Namenuk AK, Hong K, et al. High resolutionmapping of the binding site on human Ig G1 for FcγRI, FcγRII, FcγRIII, and Fc Rn and design of Ig G1 variants with improvedbinding to the FcγR. J Biol Chem 2001; 276: 6591-6604.
60. Lazar GA, Dang W, Karki S, et al. Engineered antibody Fcvariants with enhanced effector function. Proc Natl Acad Sci USA 2006; 103: 4005-10.
61. Ljunggren HG, Malmberg KJ. Prospects for the use of NKcells in immunotherapy of human cancer. Nat Rev Immunol 2007; 7: 329-39.
62. Hayday AC. γδ cells: a right time and a right place for aconserved third way of protection. Annu Rev Immunol 2000; 18: 975-1026.
63. Bonneville M, Fournie JJ. Sensing cell stress andtransformation through Vγ9Vδ2 T cell mediated recognition ofthe isoprenoid pathway metabolites. Microbes Infect 2005; 7: 503-9.
64. Kabelitz D, Wesch D, He W. Perspectives of γδ T cells intumor immunology. Cancer Res 2007; 67: 5-8.
65. Casetti R, Perretta G, Taglioni A, et al. Drug inducedexpansion and differentiation of Vγ9Vδ2 T cells in vivo: therole of exogenous IL-2. J Immunol 2005; 175: 1593-8.
66. Sicard H, Ingoure S, Luciani B, et al. In vivoimmunomanipulation of Vγ9Vδ2 T cells with a syntheticphosphoantigen in a preclinical nonhuman primate model. JImmunol 2005; 175: 5471-80.
67. Kobayashi H, Tanaka Y, Yagi J, et al. Safety profile and antitumoreffects of adoptive immunotherapy using γδ T cellsagainst advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 2007; 56: 469-76.
68. Bennouna J, Bompas E, Neidhardt EM, et al. Phase-I studyof Innacell gammadelta, an autologous cell-therapy producthighly enriched in γ9δ2 T lymphocytes, in combination withIL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 2008; 57: 1599-609.
69. Abe Y, Muto M, Nieda M, et al. Clinical and immunologicalevaluation of zoledronate-activated Vγ9 γδ T-cell-basedimmunotherapy for patients with multiple myeloma. Exp Hematol 2009; 37: 956-68.
70. Nakajima J, Murakawa T, Fukami T, et al. A phase I study ofadoptive immunotherapy for recurrent non-small-cell lungcancer patients with autologous γδ T cells. Eur J Cardiothor Surg 2010; 37: 1191-7.
71. Kobayashi H, Tanaka Y, Shimmura H, Minato N, Tanabe K. Complete remission of lung metastasis following adoptiveimmunotherapy using activated autologous γδ T-cells in apatient with renal cell carcinoma Anticancer Res 2010; 30: 575-9.
72. Dieli F, Vermijlen D, Fulfaro F, et al. Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy ofhormone-refractory prostate cancer. Cancer Res 2007; 67: 7450-7.
73. Wilhelm M, Kunzmann V, Eckstein S, et al. γδ T cells forimmune therapy of patients with lymphoid malignancies. Blood 2003; 102: 200-6.
74. Meraviglia S, Eberl M, Vermijlen D, et al. In vivo manipulationof Vgamma9Vdelta2 T cells with zoledronate and low doseinterleukin-2 for immunotherapy of advanced breast cancerpatients. Clin Exp Immunol 2010; 161: 290-7.
75. Dieli F, Gebbia N, Poccia F, et al. Induction of γδ T lymphocyteeffector functions by bisphosphonate zoledronicacid in cancer patients in vivo. Blood 2003; 102: 2310-1.
76. Dieli F, Poccia F, Lipp M, et al. Differentiation ofeffector/memory Vδ2 T cells and migratory routes in lymphnodes or inflammatory sites. J Exp Med 2003; 198: 391-7.
77. Lafont V, Liautard J, Liautard JP, Favero J. Production of TNF-α by human Vγ9Vδ2 T cells via engagement of FcγRIIIA, the low affinity type 3 receptor for the Fc portion ofIg G, expressed upon TCR activation by nonpeptidic antigen. J Immunol 2001; 166: 7190-9.
78. Angelini DF, Borsellino G, Poupot M, et al. FcγRIIIdiscriminates between two subsets of Vgamma9Vdelta2effector cells with different responses and activationpathways. Blood 2004; 104: 1801-7.
79. Poupot M, Pont F, Fournie JJ. Profiling blood lymphocyteinteractions with cancer cells uncovers the innate reactivity ofhuman γδ T cells to anaplastic large cell lymphoma. JImmunol 2005; 174: 1717-22.
80. Tokuyama H, Hagi T, Mattarollo SR, et al. Vγ9Vδ2 T cellcytotoxicity against tumor cells is enhanced by monoclonalantibody drugs: rituximab and trastuzumab. Int J Cancer 2008; 122: 2526-34.
81. Gertner-Dardenne J, Bonnafous C, Bezombes C, et al. Bromohydrin pyrophosphate enhances antibody-dependentcell-mediated cytotoxicity induced by therapeutic antibodies. Blood 2009; 113: 4875-84.
82. Gertner J, Wiedemann A, Poupot M, Fournie JJ. Human γδ T lymphocytes strip and kill tumor cells simultaneously. Immunol Lett 2007; 110: 42-53.
83. D'Asaro M, La Mendola C, Di Liberto D, et al. Vγ9Vδ2 Tlymphocytes efficiently recognize and kill zoledronatesensitized, imatinib-sensitive, and imatinib-resistant chronicmyelogenous leukemia cells. J Immunol 2010; 184: 3260-8.
84. Dieli F, Troye-Blomberg M, Ivanyi J, et al. Granulysindependentkilling of intracellular and extracellularMycobacterium tuberculosis by Vγ9Vδ2 T lymphocytes. JInfect Dis 2001; 184: 1082-5.
85. Caccamo N, Meraviglia S, Ferlazzo V, et al. Differentialrequirements for antigen or homeostatic cytokines forproliferation and differentiation of human Vγ9Vδ2 naive, memory and effector T cell subsets. Eur J Immunol 2005; 35: 1764-72.
86. Vermijlen D, Ellis P, Langford C, et al. Distinct cytokinedrivenresponses of activated blood γδ T cells: insights intounconventional T cell pleiotropy. J Immunol 2007; 178: 4304-14.
87. Kunzmann V, Wilhelm M. Anti-lymphoma effect of γδ T cells. Leuk Lymphoma 2005; 46: 671-80.
88. Martinet L, Poupot R, Fournié JJ. Pitfalls on the roadmap to γδ T cell-based cancer immunotherapies. Immunol Lett 2009; 124: 1-8.
89. Capietto AH, Martinet L, Cendron D, Fruchon S, Pont F, Fournié JJ. Phosphoantigens overcome human TCRVγ9γδ Tcell immunosuppression by TGF-β: relevance for cancerimmunotherapy. J Immunol 2010; 184: 6680-7.
90. Meeh PF, King M, O'Brien RL, et al. Characterization of the γδ T cell response to acute leukemia. Cancer Immunol Immunother 2006; 55: 1072-80.
91. Provinciali M, Re F, Tucci MG, Ricotti F, Lattanzio F. Persistent ex vivo low number and functional in vitro recoveryof circulating γδ T cells after removal of a cutaneous primarymelanoma. Scand J Immunol 2010; 72: 142-9.
92. Re F, Donnini A, Bartozzi B, Bernardini G, Provinciali M. Circulating γδ T cells in young/adult and old patients withcutaneous primary melanoma. Immun Ageing 2005; 2: 2.
93. Gaafar A, Aljurf MD, Al-Sulaiman A, et al. Defective γδ T-cellfunction and granzyme B gene polymorphism in a cohort ofnewly diagnosed breast cancer patients. Exp Hematol 2009; 37: 838-48.
94. Santini D, Martini F, Fratto ME, et al. In vivo effects ofzoledronic acid on peripheral γδ T lymphocytes in earlybreast cancer patients. Cancer Immunol Immunother 2009; 58: 31-8.
95. Bryant NL, Suarez-Cuervo C, Gillespie GY, et al. Characterization and immunotherapeutic potential of γδ Tcellsin patients with glioblastoma. Neuro Oncol 2009; 11: 357-67.
96. Braza MS, Caraux A, Rousset T, et al. γδ T lymphocytescount is normal and expandable in peripheral blood ofpatients with follicular lymphoma, whereas it is decreased intumor lymph nodes compared with inflammatory lymphnodes. J Immunol 2010; 184: 134-40.
97. Maniar A, Zhang X, Lin W, Gastman BR, Pauza CD, Strome SE, Chapoval AI. Human γδ T lymphocytes induce robust NKcell mediated antitumor cytotoxicity through CD137engagement. Blood 2010 [Epub ahead of print].
98. Kong Y, Cao W, Xi X, Ma C, Cui L, He W. The NKG2D ligandULBP4 binds to TCRUU9/992 and induces cytotoxicity to tumorcells through both TCRγδ and NKG2D. Blood 2009; 114: 310-7.
99. Lança T, Correia DV, Moita CF, et al. The MHC class Ibprotein ULBP1 is a nonredundant determinant ofleukemia/lymphoma susceptibility to γδ T-cell cytotoxicity. Blood 2010; 115: 2407-11.